Dunia de Miguel

Risk factors and outcome of COVID-19 in patients with hematological malignancies

José Luís Piñana, Rodrigo Martino, Irene García‐García et al. · Experimental Hematology and Oncology · 2020 · 158 citations · Full text

Medicine, Hematology, Oncology +13

Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: Impact of novel therapies

Julio García‐Suárez, Dunia de Miguel, Isabel Krsnik et al. · American Journal of Hematology · 2005 · 118 citations · Full text

Life Sciences, Infectious Diseases, Pharmacology +7

Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia

Regina García‐Delgado, Dunia de Miguel, Alicia Bailén et al. · Leukemia Research · 2014 · 50 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Dose‐adjusted EPOCH plus rituximab is an effective regimen in patients with poor‐prognostic untreated diffuse large B‐cell lymphoma: results from a prospective observational study

Julio García‐Suárez, Helena Bañas, Ignacio Arribas et al. · British Journal of Haematology · 2006 · 45 citations · Full text

Medicine, Hematology, Oncology +14

Platelet Dysfunction in Primary Thrombocythemia Using the Platelet Function Analyzer, PFA-100

Jesús M. Cesar, Dunia de Miguel, A. García Avello et al. · American Journal of Clinical Pathology · 2005 · 36 citations

Medicine, Hematology, Hematology Physiology +11